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Abstract 
Background: The enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) 
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tissues. Its dysregulation has been implicated in a wide array of metabolic diseases, 
leading to the development of selective 11β-HSD1 inhibitors. We examined the impact 
of the reversible competitive 11β-HSD1 inhibitor, AZD4017, on the metabolic profile in an 
overweight female cohort with idiopathic intracranial hypertension (IIH).
Methods: We conducted a UK multicenter phase II randomized, double-blind, placebo-
controlled trial of 12-week treatment with AZD4017. Serum markers of glucose 
homeostasis, lipid metabolism, renal and hepatic function, inflammation and androgen 
profiles were determined and examined in relation to changes in fat and lean mass by 
dual-energy X-ray absorptiometry.
Results: Patients receiving AZD4017 showed significant improvements in lipid profiles 
(decreased cholesterol, increased high-density lipoprotein [HDL] and cholesterol/HDL 
ratio), markers of hepatic function (decreased alkaline phosphatase and gamma-glutamyl 
transferase), and increased lean muscle mass (1.8%, P < .001). No changes in body mass 
index, fat mass, and markers of glucose metabolism or inflammation were observed. 
Patients receiving AZD4017 demonstrated increased levels of circulating androgens, 
positively correlated with changes in total lean muscle mass.
Conclusions: These beneficial metabolic changes represent a reduction in risk factors 
associated with raised intracranial pressure and represent further beneficial therapeutic 
outcomes of 11β-HSD1 inhibition by AZD4017 in this overweight IIH cohort. In particular, 
beneficial changes in lean muscle mass associated with AZD4017 may reflect new 
applications for this nature of inhibitor in the management of conditions such as 
sarcopenia.
Key Words: 11b-HSD1, AZD4017, 11b-HSD1 inhibitor, Idiopathic intracranial hypertension, cortisol
Glucocorticoids are a class of pleiotropic steroid hor-
mones with diverse effects on systemic metabolism that in 
excess promote insulin resistance, obesity, hypertension, 
and dyslipidemia (1). The enzyme 11β-hydroxysteroid de-
hydrogenase type 1 (11β-HSD1) primarily converts the 
inactive glucocorticoid cortisone to its active counterpart 
cortisol (2). Its dysregulation and elevated activity within 
peripheral tissues results in an increased exposure to ac-
tive glucocorticoids, and have been implicated in a wide 
array of diseases including type 2 diabetes mellitus, cardio-
vascular disease, metabolic syndrome, osteoporosis, hyper-
tension, nonalcoholic fatty liver disease, and Alzheimer’s 
disease (3-6).
Consequently, multiple pharmacological 11β-HSD1 
inhibitors, including MK-0736, MK-0916, RO-151, ABT-
384, and INCB13739 have been developed for the man-
agement of these conditions, and examined in phase II 
clinical trials (7-13). Several of these studies demonstrated 
that these drugs are well tolerated and yield improvements 
in measures of glycated hemoglobin (HbA1c), low-density 
lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, liver fat content, and body weights 
when administered for up to 12 weeks, (7, 10, 12, 13). 
While these studies demonstrated differences in the efficacy 
of this class of inhibitors between different patient cohorts, 
including type 2 diabetes and hypertension, the magnitude 
of this benefit proved insufficient compared with existing 
standard drugs for disease management. However, the di-
verse metabolic targets of 11β-HSD1 inhibitors remain a 
notable and unique strength in their application. Further 
refinements to 11β-HSD1 inhibitors have continued to 
identify new compounds with more favorable therapeutic 
properties. The nicotinic amide–derived carboxylic acid 
class of 11β-HSD1 inhibitors (including AZD4017) are 1 
such family of compounds that show favorable potency, 
selectivity, and pharmacokinetic properties (median inhibi-
tory concentration [IC
50] 0.007 µM) (14).
One particular area of interest identified for 11β-HSD1 
inhibitors has been the management of idiopathic intra-
cranial hypertension (IIH). This condition, character-
ized by raised intracranial pressure, papilledema, chronic 
headaches, and reduced quality of life also shows signifi-
cant correlation between changes in 11β-HSD1 activity in 
the choroid plexus and changes in intracranial pressure, 
indicating a possible role in disease pathophysiology (15-
17). In IIH cohorts, this occurs in combination with meta-
bolic dysregulation and obesity, which are themselves risk 
factors for developing IIH and potential targets for 11β-
HSD1 inhibitors (18, 19). The application of AZD4017 
in the management of IIH and raised intracranial pressure 
has now been examined in a phase II clinical trial (6, 20). 
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relationship between 11β-HSD1 inhibition and reduction 
in intracranial pressure. However, the wider metabolic and 
inflammatory effects of AZD4017 in this IIH patient co-
hort have yet to be fully examined.
This study investigates the consequences of 12-week 
11β-HSD1 inhibition on insulin sensitivity, body weight 
and composition, lipid profiles, liver and renal function, 
systemic and central nervous system inflammation, and 
glucocorticoid and androgen pathways in a cohort of 
young obese women with a diagnosis of IIH.
Patients and Methods
Study conduct
This multicenter UK study was conducted from March 
2014 to December 2016. The National Research Ethics 
Committee York and Humber-Leeds West gave eth-
ical approval (13/YH/0366). All patients provided 
written informed consent in accordance with the declar-
ation of Helsinki. The trial is registered at Clinicaltrials.
gov NCT02017444; European Clinical Trials Database 
(EudraCT Number: 2013-003643-31). The detailed clin-
ical trial methodology has been published (20).
Study population
Obese women aged 18 to 55 years were recruited who were 
otherwise healthy except for a diagnosis of IIH (21, 22). 
Exclusion criteria were a significant past medical history 
including thyroid disease, other complex endocrine disease, 
renal failure, liver failure, hypertension (blood pressure 
>160  mmHg systolic), systemic (including vaginal/rectal) 
glucocorticoid treatment, hormone-based medication, 
including hormone contraceptives, probenecid intake, and 
any medical/surgical procedure or trauma within 4 weeks 
prior to study enrolment. Coexisting medications are re-
ported elsewhere (all supplementary material and figures 
are located in a digital research materials repository (23)).
Study design
A UK multicenter double-blind placebo-controlled ran-
domized controlled trial with a 12-week dosing duration 
and 4-week follow-up off drug (total duration 16 weeks). 
Participants were randomized to either an oral selective 
11β-HSD1 inhibitor, AZD4017, at 400 mg twice daily, or a 
matched placebo for 12 weeks.
Randomization: The IIHDT randomization notepad 
was used, and after venesection on the baseline day the 
number was allocated by University Hospitals Birmingham 
pharmacy (20). Patients were allocated a trial number 
randomly by phone, using block-of-6 randomization. 
The study investigators, nurses, and participants were all 
blinded to the treatment allocation during the trial.
Assessments
All participants underwent a detailed medical history and 
examination. Assessments were conducted at 10 visits over 
a 16-week period (full assessment protocol detailed in (6) 
and 20). All blood samples were collected following an 
overnight fast (from midnight). Lumbar punctures were 
conducted in the left lateral decubitus with knees bent at 
a 90° angle or more and intracranial pressure recorded be-
fore cerebrospinal fluid (CSF) was collected (up to 15 mL). 
Body mass index (BMI) was measured from height (Seca 
Leicester height measure, Birmingham, UK) and weight 
(Seca 677 electronic wheelchair scale, Birmingham, UK) 
using the following formula: BMI  =  (weight (kg)/height 
(m)2). Adverse events were recorded along with drug com-
pliance (unused medication documented).
Fasting insulin and HOMA2-IR
Fasting insulin (Mercodia, Uppsala, Sweden) was meas-
ured using a commercially available assay, according to 
the manufacturer’s instructions. Homeostasis model as-
sessment of insulin resistance (HOMA2-IR) was calculated 
using the program HOMA calculator v2.2.3 (24).
Blood and cerebrospinal fluid biochemical 
analysis
The following fasted bloods were processed at the hospital 
laboratory: glucose, HbA1c, cholesterol, HDLs, and trigly-
cerides, liver and kidney function tests including, alkaline 
phosphatase (ALP), gamma-glutamyl transferase (GGT), 
aspartate transaminase (AST), alanine aminotransferase 
(ALT), bilirubin, creatinine, estimated glomerular filtration 
rate (eGFR), and creatinine kinase (CK). Samples not ana-
lyzed immediately were centrifuged (10 minutes at 1500g 
at 4°C) aliquoted and stored at –80°C. CSF samples were 
centrifuged (800g for 10 minutes at 4°C) and the super-
natant was aliquoted and stored at –80°C. All samples pro-
cessed only underwent a single freeze–thaw cycle.
Cytokines, adipokines, and bone marker analysis
Serum (1 in 2 dilution) and CSF interleukin (IL)-8, leptin, 
and MCP-1 were measured using the Procarta Multiplex 
immunoassay (Thermo Fisher Scientific) with lower 
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mL respectively. Serum (1 in 2 dilution) and CSF IL-1β, 
IL-10, IL-6, and TNF-α were measured using the Procarta 
High Sensitivity Multiplex immunoassay (Thermo Fisher 
Scientific) with lower limits of detection of 0.145 pg/mL, 
0.039  pg/mL, 0.038  pg/mL, 0.215  pg/mL.  respectively. 
Serum (1 in 500 dilution) and CSF adiponectin was meas-
ured using the Procarta Singleplex immunoassay (Thermo 
Fisher Scientific) with lower limits of detection of 4.6 pg/
mL. Serum osteocalcin (OC) and sclerostin (SC) were meas-
ured using the Milliplex MAP Human Bone Magnetic Bead 
Panel (Millipore) with lower limits of detection of 68.5 pg/
mL and 31.1 pg/mL, respectively. All assays were conducted 
according to the manufacturer’s instructions and were ana-
lyzed using a Luminex 100/200 system.
Serum steroid profiling by liquid 
chromatography-tandem mass spectrometry
Serum steroids were analyzed using liquid chromatography-
tandem mass spectrometry (LC-MS/MS), as previously de-
scribed (25-27). An internal standard mixture was added to 
400 µL of serum. Steroids were extracted via liquid/liquid 
extraction with 2 mL of tert-butyl methyl ether (MTBE). 
The MTBE layer was removed, evaporated to dryness, and 
reconstituted in methanol/water prior to LC-MS/MS ana-
lysis. The extracts were analyzed on a Xevo TQ-S triple 
quadrupole mass spectrometer (Waters) coupled to an 
Acquity ultrahigh-performance liquid chromatography 
system (UPLC) (Waters). Steroids were separated on a 
HSS T3 (1.8 µm) column (Waters) using a methanol/water 
gradient (both with 0.1% formic acid). Starting condi-
tions was 45% methanol, which was held for 1 minute, 
followed by a linear gradient to 75% methanol at 5 
minutes. Subsequently, the column was washed at 98% 
methanol and reconditioned at starting condition prior 
to the next injection. Steroids were identified and quanti-
fied via comparison to reference standards; positive iden-
tification was confirmed via matching retention time and 
two identical mass transitions. Steroids quantified were 
testosterone, androstenedione, dehydroepiandrosterone 
(DHEA), cortisol, 11-ketoandrostenedione and 
11β-hydroxyandrostenedione. The calibration series 
ranged from 0.01 to 250 ng/mL (including a blank and a 
0 ng/mL calibrator).
Dual-energy X-ray absorptiometry 
Dual-energy X-ray absorptiometry (DXA) was performed 
using a total-body scanner (QDR 4500; Hologic), as pre-
viously described (28). Patients with metal prosthetics or 
implants were included, and tissue overlying the prosthesis 
was excluded from analysis. Scans were checked for ac-
curacy of fields of measurement. Regional fat mass was 
analyzed as described previously (28). The precision of 
total fat mass measures in terms of coefficient of variation 
(CV) was less than 3%, and for regional fat analyses it was 
less than 5%. Regional fat data were expressed as a per-
centage of the total body fat.
Statistical analysis
The trial was powered to assess clinical efficacy in IIH 
but not changes in metabolic parameters (20). All patients 
were invited for all assessments within the trial. Any ab-
sent patient data reflected individual choice to omit a test. 
Statistical analysis was performed using Graphpad prism 8 
(Graphpad Software Inc). The data are presented as mean 
and standard error of the mean. Differences between values 
at baseline and 3 months were tested using 2-way analysis 
of variance or mixed effects analysis to account for missing 
data points and 95% confidence intervals noted. Multiple 
comparisons were conducted to compare week 0 with week 
12 in each of treatment groups, and P values were adjusted 
using Sidak’s multiple comparison test. Spearman’s rank 
correlation coefficient was used for assessing correlations. 
Results were judged statistically significant at P < .05.
Results
Patient cohort and clinical characteristics
This study was a double-blind randomized placebo-
controlled trial of the 11β-HSD1 inhibitor AZD4017 for 
12 weeks in 31 women with active IIH. Seventeen partici-
pants received AZD4017 (no withdrawals) and 14 parti-
cipants received placebo (1 withdrawal due to an adverse 
event deemed unrelated to the study, 1 loss to follow-up) 
(Fig. 1). Complete study design, pharmacodynamic efficacy 
of 11β-HSD1 inhibition, effect on IIH disease measures, 
and adverse event profile have previously been reported 
(6). In brief, the patient cohort had an average age of 
31.2 ± 6.9 years, weight of 102.6 ± 32.3 kg, and BMI of 
39.2  ±  12.6  kg/m2. There were no significant differences 
in baseline characteristics between the trial arms (Table 1).
Pharmacological efficacy of AZD4017
The pharmacological properties of AZD4017 to in-
hibit 11β-HSD1 with high efficacy and specificity 
have previously been validated in phase I  and II trials 
(6, 14). In brief, AZD4017 inhibits human 11β-HSD1 
at IC50  =  0.007  μM, contrasting with IC50  >  30  μM 
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or 17β-HSD3 (14). Treatment with AZD4017 in the 
clinical trial resulted in 70% suppression of systemic 
11β-HSD1 activity as measured by 24-hour urinary 
5α-tetrahydrocortisol + tetrahydrocortisol):tetrahydroco
rtisone ratio (0.27 ± 0.29 vs 0.90 ± 0.28; P < .0001) (6). 
Liver is the main site for 11β-HSD1 activity in vivo and 
efficacy for this tissue was assessed separately through 
a non-invasive pharmacodynamic study. Hepatic 11β-
HSD1 activity was suppressed by 85.9% as measured by 
the conversion rate of orally administered prednisone to 
prednisolone (area under the curve analysis 228 ± 99 vs 
1738 ± 142; P <  .0001) (6). Clinical endpoint data for 
AZD4017 have been reported from 1 phase II trial. Here, 
in a patient cohort with idiopathic intracranial hyper-
tension receiving 400 mg of oral AZD4017 twice daily, 
versus placebo over 12 weeks, the primary outcome 
was lumbar puncture opening pressure. Reduction of 
serum cortisol:cortisone ratio observed with AZD4017 
treatment correlated with decreased intracranial pres-
sure (r = 0.70; P =  .005; n = 15) (6). Intracranial pres-
sure reduced in those taking AZD4017 (mean change: 
−4.3 cmH2O [SD = 5.7], P = .009) but there was no sig-
nificant difference between arms (–2.8  cmH2O; 95% 
confidence interval: –7.1 to 1.5 cmH2O; P = .2; n = 31) 
(6). In summary, the data demonstrate that AZD4017 
specifically inhibits 11β-HSD1 activity in vivo.
Glucose homeostasis and Lipid metabolism
We examined serum measures of both glucose homeostasis 
and lipid metabolism (Fig. 2A-H). No significant changes 
in fasting glucose, fasting insulin, HOMA2-IR and HbA1c 
were apparent in either treatment group at 12 weeks rela-
tive to baseline (Fig. 2A-D and (23). Analysis of lipid me-
tabolism revealed reduced cholesterol (–7.9%, P  <  .01), 
increased HDL (8.2%1, P  <  .05) and a decreased chol-
esterol/HDL ratio (–17.4%, P < .01) at 12 weeks relative 
Figure 1. Trial design and participant numbers for double-blind, placebo-controlled, randomized controlled trial in IIH using the selective 11β-HSD1 
inhibitor AZD4017.
Table 1. Baseline characteristics of idiopathic intracranial 








Age in years (SD) 32.4 (8.0) 30.1 (5.9) 31.2 (6.9)
Ethnicity, n (%)    
White British 13 (93) 16 (94) 29 (94)
Asian/Asian British – 
Pakistani
0 (0) 1 (6) 1 (3)
Asian/Asian British – 
0ther Asian
1 (7) 0 (0) 1 (3)
Weight, kg (SD) 108.4 (42.3) 97.9 (21.3) 102.6 (32.3)
BMI (weight (kg)/ 
height (m2) (SD)
41.2 (16.6) 37.3 (7.2) 39.2 (12.6)
No significant differences were found between groups for any of the 
parameters.







/article/106/1/174/5938445 by Ian N
orthover on 25 M
arch 2021
The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 1 179
to baseline in the AZD4017 group, but not in the placebo 
group (Fig. 2E-H and (23)). Triglyceride levels remained 
unchanged in both groups. Together, these data indicate 
that while glucose homeostasis appeared to be largely 
unaffected in this normoglycemic cohort, 12 weeks of 
AZD4017 treatment had beneficial effects on serum chol-
esterol profiles.
Liver and renal function and systemic and central 
nervous system inflammation
Liver and renal function and systemic measures of inflam-
mation were evaluated in patients receiving placebo and 
AZD4017 throughout the study. In both groups, surro-
gate markers for liver and renal function were within the 
normal reference range at baseline. No changes in these 
markers were apparent in patients receiving placebo at 12 
weeks relative to baseline (Fig. 3A-H and (23)). Similarly, 
no significant changes in bilirubin, ALT and AST levels 
were apparent in patients receiving AZD4017 at 12 weeks 
relative to baseline (Fig. 3A-C). However, ALP and GGT 
significantly decreased in patients receiving AZD4017 
relative to baseline (ALP, –20.5%, P  >  .0001; GGT, 
–29.3%, P > .0001) (Fig. 3D and 3E). Within the normal 
reference range, we observed a significant increase in serum 
creatinine levels (8.5%, P < .0001) and decrease in eGFR 
(–7.5%, P < .001) in patients receiving AZD4017 relative 
to baseline at 0 weeks, with no correlation observed to lean 
muscle mass (23). In contrast, no changes were evident in 
the placebo treated groups relative to baseline.
Serum levels of the inflammatory cytokines IL-6, IL-8, 
IL-10, MCP-1, and TNF-α were not affected by treat-
ment with AZD4017 (23). Similarly, CSF levels of IL-6, 
IL-8, and MCP-1 were also unaffected by AZD4017 
treatment, with IL-10 and TNF-α levels below the limit 
of detection. Levels of osteoblast marker osteocalcin 
and negative regulator of bone formation sclerostin did 
not change relative to baseline levels in placebo and 
AZD4017 groups (23). Together, these data indicate that 
the inhibitor AZD4017 had limited effects on markers 
of liver function, with reductions in only ALP and GGT, 
without increasing systemic or CSF inflammation. While 
not clinically significant, surveillance of renal function 
using serum creatinine suggests a small but statistically 
Figure 2. Metabolic changes following 12 weeks of AZD4017 treatment in IIH patients. Histograms showing glucose (A), insulin (B), HOMA2-IR (C), 
HbA1c (D), triglycerides (E), cholesterol (F), HDL (G), and the cholesterol/HDL ratio (H) in IIH patients before and after 12 weeks of either placebo or 
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significant decrease in eGFR (within normal parameters) 
in patients receiving AZD4017.
Body weight, fat mass, and musculoskeletal 
parameters
To assess the impact of 11β-HSD1 inhibition with AZD4017 
on fat and lean mass and mass we examined body compos-
ition using DXA measurements. No significant changes were 
observed for total body weight, BMI, total fat mass, regional 
fat distribution (trunk, limb, android, or visceral) and bone 
mineral content in either group relative to baseline (Tables 1 
and 2). In contrast, total lean mass increased from baseline 
to 12 weeks in the treatment group (48  904  ±  6020  g vs 
49 493 ± 6008 g, + 1.2%; P < .001), but not in the placebo 
group (Fig. 4A). Closer examination of proximal and distal 
lean mass revealed that this increase in muscle mass was not 
specific to either compartment with comparable increases 
in both groups (proximal, +1.1%; P  <  .05; distal, +1.0%; 
P < .05) (Fig. 4B and 4C). Together, these data indicate that 
inhibition of 11β-HSD1 with AZD4017 in obese females for 
12 weeks did not alter adipose or bone tissue composition but 
led to a modest increase in muscle mass.
Steroid metabolism
Inhibition of tissue cortisol activation by 11β-HSD1 may 
lead to secondary activation of the hypothalamic pituitary 
adrenal (HPA) axis. While circulating serum cortisol levels 
appeared unchanged in human studies with 11β-HSD1 in-
hibitors, there were indications of increased adrenocortico-
tropin (ACTH) secretion and adrenal androgen production 
(Table  3) (7, 10, 12). To obtain a comprehensive picture 
how 11β-HSD1 inhibition may impact on steroid metab-
olism in humans, we performed serum steroid metabolome 
profiling by LC-MS/MS in our IIH cohort.
As previously reported, measures of systemic 11β-HSD1 
activation of cortisone to cortisol were significantly de-
creased in line with systemic inhibition of 11β-HSD1 (–1.1; 
P < .001) (Table 3) (6). In addition, we observed a significant 
decrease in cortisol:DHEA ratio (14.09 ± 0.9 vs 7.8 ± 0.7, 
P < .001) in patients receiving AZD4017 at 12 weeks rela-
tive to baseline (Table  3). Analysis of serum androgens 
revealed an increase following treatment with AZD4017 
(Fig. 5A and 5B). This increase did not reach significance 
for DHEA and androstenedione; however, there was a sig-
nificant increase in testosterone (0.71  ±  0.15 vs baseline 
1.10 ± 0.16 nmol/L, P < .01) 11β-hydroxyandrostenedione 
Figure 3. Liver enzymes and kidney function changes following 12 weeks of AZD4017 treatment in IIH patients. Histograms showing (A) bilirubin, (B) 
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(3.37  ±  0.44 vs 6.28  ±  1.02  nmol/L, P  <  .01) and 
11-ketoandrostenedione (0.96 ± 0.8 vs 1.46 ± 0.17 nmol/L, 
P < .001) (Table 3). The rise in serum androgen levels was 
accompanied by a trend for higher urinary excretion of an-
drogens and associated metabolites, although differences 
before and after treatment did not research statistical sig-
nificance for the AZD4017 subgroup with available data 
(23). Of note, changes in total lean mass were shown to 
be positively correlated with the increase in serum testos-
terone (r = 0.651, P =  .030), androstenedione (r = 0.855, 
P =  .001), and 11-ketoandrostenedione (0.618, P =  .043) 
(Fig. 5D-F).
Discussion
Therapeutic inhibition of 11β-HSD1 activity is of consid-
erable interest in diverse metabolic diseases, for example, 
obesity, diabetes, metabolic syndrome, and nonalcoholic 
fatty liver disease (7, 8, 10, 12, 13). The nicotinic amide 
derived carboxylic acid AZD4017 has been developed as 
a reversible, highly potent and selective inhibitor of 11β-
HSD1 with favorable pharmacokinetics (14). In addition 
to interest in its application in the management of IIH, it 
has also recently been evaluated in phase II clinical trials 
for the management of Iatrogenic Cushing’s syndrome 
and in postmenopausal women with osteopenia (TICSI, 
ID: NCT03111810, MICA, ID: MR/K015176/1). In this 
report, we detail the effects of sustained 11β-HSD1 in-
hibition with AZD4017 over 12 weeks on parameters of 
metabolism, body composition, steroid metabolome, and 
inflammatory cytokine signaling in an overweight patient 
cohort with IIH.
The use of serial DXA assessments allowed us to ana-
lyze changes in body composition with therapeutic 11β-
HSD1 inhibition in greater detail than in previous clinical 
trials. Total lean muscle mass increased in the AZD4017 
treatment group over 12 weeks, but no change was ob-
served in the control group. The observed difference of 
1.2% lean muscle mass over 12 weeks is considerable, 
given that the magnitude of change is similar to that ob-
served for muscle wasting in the elderly population of 1% 
to 2% per year (29). Increased lean muscle mass may re-
sult directly from inhibition of glucocorticoid activation 
within skeletal muscle tissue. Mature skeletal muscle fibers 
express 11β-HSD1 with cortisol-activating activity as well 
as glucocorticoid receptors (25). Overall, glucocorticoid 
stimulation has an antianabolic, atrophic effect on skel-
etal muscle tissue (30, 31). Our data and previous studies 
demonstrate that serum cortisol levels are not affected 
by therapeutic 11β-HSD1 inhibition (7, 10, 12), meaning 
that circulating cortisol levels cannot adequately account 
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Figure 4. Alterations in (A) total lean mass, (B) proximal lean mass and (c) distal lean mass in grams, determined by DXA following 12 weeks treat-
ments with either placebo (n = 10) or AZD4017 treatment (n = 12) in IIH patients. *P < .05; **P < .01.
Table 3. Serum steroid analysis by LC-MS/MS in an idiopathic intracranial hypertension (IIH) cohort receiving either placebo 
or the 11β-HSD1 inhibitor AZD4017 at baseline and at 12 weeks
Serum concentrations in nmol/L (Median ± IQR)
Placebo (n = 11–12) AZD4017 (n = 16)
Baseline 12 Weeks Difference Baseline 12 Weeks Difference 
Cortisol 185.3 ± 124.7 184.5 ± 105.0 –0.8, P = .8 195.6 ± 119.3 158.2 ± 104.1 –37.4, P = .6
Cortisone 38.3 ± 12.9 36.9 ± 19.4 –1.4, P = .8 43.9 ± 22.8 42.6 ± 27.8 –1.3, P = .1
Cortisol:cortisone ratio 4.9 ± 1.4 4.7 ± 1.1 –0.2, P = .8 4.8 ± 1.8 3.4 ± 1.6 –1.4, P = .01
Cortisol: DHEA ratio 11.0 ± 12.0 9.7 ± 14.0 –1.3, P = .1 13.4 ± 8.0 7.0 ± 4.6 –6.4, P = .01
Testosterone 0.8 ± 0.9 1.0 ± 1.1 0.2, P = .4 0.4 ± 1.0 1.0 ± 1.1 0.6, P = .01
A4 3.9 ± 3.6 4.9 ± 4.6 1.0, P = .2 3.9 ± 2.9 5.0 ± 2.4 1.1, P = .1
DHEA 14.0 ± 15.6 17.6 ± 15.6 3.6, P = .5 15.5 ± 9.7 22.7 ± 12.5 7.2, P = .08
11OHA4 2.7 ± 2.6 3.8 ± 4.2 1.1, P = .9 2.8 ± 3.0 5.7 ± 1.8 2.9, P = .01
11KA4 0.9 ± 0.2 0.9 ± 0.4 0.0, P = .8 0.9 ± 0.5 1.3 ± 0.4 0.4, P = .01
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glucocorticoid signaling within muscle tissue may be sig-
nificant. In support of this hypothesis, skeletal muscle 11β-
HSD1 expression has been shown to correlate negatively 
with muscle size and strength in aging humans (25). To 
further investigate whether local suppression of 11β-HSD1 
activity within skeletal muscle has anticatabolic effects 
would require examination of tissue-specific pharmaco-
logical actions, either in muscle biopsies or through tissue-
selective pharmacodynamic studies. While such procedures 
were outside the remit of our original clinical trial protocol, 
our results on increased lean muscle mass with AZD4017 
treatment strengthen the rationale to address this question 
in future research.
Alternatively, the increased lean muscle mass observed in 
the IIH cohort, may result indirectly from systemic changes 
in androgen concentration and signaling. Here, a rise in 
circulating androgen levels within the normal range was 
observed in the AZD4017 treatment group and has been a 
consistent finding in clinical trials of 11β-HSD1 inhibitors 
(7, 10, 12). Importantly, androgen receptors are expressed in 
muscle precursor cells and mature muscle fibers, where they 
induce myogenesis and muscular hypertrophy and mediate 
increased lean muscle mass in response to increased circu-
lating androgen levels (32, 33). Supporting this concept, the 
increases in testosterone and the androgen pro-hormones 
11β-hydroxy and 11-ketoandrostenedione metabolites 
(that are converted to androgenic 11-ketotesosterone) 
showed a positive correlation with increased lean mass in 
patients receiving AZD4017. However, we did not measure 
the circulating concentrations of the active 11-oxygenated 
androgen 11-ketotestosterone (34), or examine androgen 
effects in skeletal muscle tissue directly. Acknowledging 
these limitations, our data indicate that the positive effects 
of 11β-HSD1 inhibitors on muscle mass may be mediated 
through increased anabolic androgen signaling, with fur-
ther research needed to confirm precise pharmacological 
actions in skeletal muscle tissue. Regardless, these novel 
observations of increased lean muscle mass observed in pa-
tients receiving the 11β-HSD1 inhibitor AZD4017 raise a 
question of potential benefits in conditions that are associ-
ated with muscle wasting. This hypothesis warrants further 
research.
Previous studies report compensatory activation of the 
HPA axis as a consequence of 11β-HSD1 inhibition, with 
modest increases in circulating ACTH and DHEA concen-
trations (within the respective normal reference ranges) in 
both male and female patients (7, 10, 12). Elevated ACTH 
levels were also apparent in this overweight IIH cohort re-
ceiving AZD4017 (data reported in (6)). Here, we evaluated 
serum androgens in this overweight IIH cohort receiving 
AZD4017. We observed trends towards increased DHEA, 
with significant increases in testosterone, androstenedione, 
and 11-oxygenated androgen prohormones, supporting 
previous findings (7, 10, 12). The accompanying trend 
for increased urinary excretion of androgens and associ-
ated metabolites suggests that reduced renal clearance of 
androgens does not account for these findings. Although 
androgen levels remained within the normal range, these 
data support the concept of a modest HPA axis activa-
tion and increased adrenal androgen synthesis. Additional 
Figure 5. Changes in the androgens (A) testosterone, (B) 11-ketoandrostenedione and (C) 11β-hydroxyandrostenedione in serum following 12 weeks 
of AZD4017 treatment in IIH patients. Correlations between changes in the androgens (D) testosterone, (E) 11β-hydroxyandrostenedione and (F) 
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factors that may contribute to our findings include a re-
duction in the activation of 11-oxygenated androgens by 
11β-HSD1 and would require closer investigation in the 
future (26). In ours, and prior studies, elevated serum an-
drogen concentrations were not associated with clinically 
evident hirsutism, although the timeframes of this study 
may be insufficient to adequately assess this, and will merit 
closer examination in future studies, given prior reports of 
androgen excess IIH (27).
Modest weight loss or reduction in BMI have been re-
ported in several clinical trials of 11β-HSD1 inhibitors (7, 
10, 12, 35, 36). However, we did not observe changes in 
total body weight or BMI, total body fat mass, or depot–
specific fat mass. Similarly, no changes in blood pressure 
were evident in patients receiving AZD4017 (data not 
shown). These findings may reflect differences in pharma-
codynamic properties of AZD4017 relative to other 11β-
HSD1 inhibitors. We observed that systemic administration 
of AZD4017 had limited capacity to suppress 11β-HSD1 
activity in adipose tissue biopsies at 12 weeks (6). This may 
reflect the reversible nature of this competitive inhibitor, 
which would allow diffusion of the inhibitor out of the 
fat biopsy sample into the substantially larger culture me-
dium volume during the ex vivo activity assay, rendering 
its concentration ineffective. However, AZD4017 effect-
ively blocked 11β-HSD1 activity both in subcutaneous and 
omental adipose tissue explants at 200 nM, a substantially 
lower concentration than average serum levels of 4671 nM 
in the treatment group (6). Alternatively, this could also be 
consistent with a phenomenon of reduced pharmacological 
effect with prolonged exposure, which has already been de-
scribed to limit sustained suppression of 11β-HSD1 activity 
in human adipose tissue with other systemically adminis-
tered agents (37). Another consideration could be that this 
overweight female cohort may be less responsive to weight 
loss properties of 11β-HSD1 inhibitors compared with pa-
tient cohorts with type 2 diabetes and metabolic syndrome.
Bone mineral density and markers of bone turnover 
were not significantly changed with AZD4017 treatment. 
The relevance of 11β-HSD1 activity for bone health has be-
come of interest, owing to the well-established detrimental 
effects of glucocorticoid excess on bone health and animal 
models suggesting 11β-HSD1 activity inhibits bone forma-
tion (30, 38). However, 12 weeks may be an insufficient 
timeframe in which to measure meaningful changes in bone 
metabolism. Alternatively, the absence of risk factors for 
bone mineral loss in this pre-menopausal study cohort may 
reduce the potential to detect effects of 11β-HSD1 inhib-
ition on bone composition.
Robust improvements in glucose homeostasis have 
been reported in response to 11β-HSD1 inhibitors in both 
murine models of diabetes and obesity and in phase II 
clinical trials in patients with type 2 diabetes and meta-
bolic syndrome, with reductions in fasting insulin, blood 
glucose, HbA1c, and HOMA2-IR (7, 10, 13, 35, 39-41). 
No significant changes in any of these parameters were de-
tected in patients receiving placebo or AZD4017 relative 
to baseline at 12 weeks. As with body weight, these data 
suggest that as the non-diabetic, healthy obese IIH cohort 
examined in this trial would be less responsive to this prop-
erty of AZD4017.
In contrast, we observed favorable changes in lipid pro-
files in patients receiving AZD4017, closely reflecting those 
seen in comparable murine models of obesity and clinical 
trials examining 11β-HSD1 inhibitors (10, 12, 39, 42). 
Previously, Rosenstock et al. (10) reported a significant de-
crease in cholesterol, LDL cholesterol, and triglycerides in 
hyperlipidemic patients, but Shah et al. (12) saw significant 
decreases in LDL cholesterol and HDL cholesterol, but not 
triglycerides in patients in higher BMI overweight groups. 
In this statin naïve overweight IIH cohort, total cholesterol, 
and LDL cholesterol were reduced relative to baseline in 
patients receiving AZD4017, whereas HDL cholesterol was 
increased, supporting the concept that 11β-HSD1 inhibi-
tors may be effective at improving harmful lipid profiles 
in this context. Consequently, in addition to the direct in-
hibition of 11β-HSD1 activity and CSF production in the 
choroid plexus of IIH patients, as proposed by Sinclair 
et al., secondary improvements in IIH risk factors such as 
lipid metabolism and obesity may also be realized in pa-
tients receiving AZD4017, offering further therapeutic 
efficacy (15, 18, 19). Particularly, given the increased inci-
dence of adverse cardiovascular outcomes reported in IIH 
patients relative to matched controls, AZD4017 may prove 
an effective adjunct in IIH to reduce cardiovascular risk 
(43).
Lastly, liver, and renal function and measures of sys-
temic and central nervous system inflammation were as-
sessed in this overweight IIH cohort receiving AZD4017. 
These revealed some positive effects on markers of liver 
function, with significant decreases in both ALP and 
GGT. The mechanism underpinning this remains unclear, 
although previous studies in mice have demonstrated 
protection from fat accumulation and hepatic steatosis 
within the livers of mice with transgenic deletion of 11β-
HSD1 (44). However, in this study, the reported changes 
were modest and their clinical relevance remains un-
clear. Similarly, changes in serum creatinine, and hence 
eGFR, were also small and not clinically significant in 
this population with normal renal function at baseline. It 
is important to note that serum creatinine levels are sig-
nificantly influenced by lean muscle mass as well as renal 
clearance, reducing their accuracy as a marker of kidney 
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lean body mass, as seen in our cohort (45). On further 
scrutiny, observed serum creatinine changes were not 
concordant with changes in lean muscle mass or changes 
in serum urea (data reported in (6)) to support either a 
non-renal or renal explanation respectively. No changes 
in renal markers have been reported in previous studies 
examining 11β-HSD1 inhibitors. Hence, our data can 
neither confirm nor deny that inhibition of 11β-HSD1 
with AZD4017 may negatively impact on kidney func-
tion. Further research will be needed to address this 
important question and should involve more specific 
measures of glomerular filtration rate.
11β-HSD1 activity, which is potently stimulated by in-
flammatory stimuli, is emerging as an important feedback 
regulator of local tissue damage related to inflammation 
(46-48). To address concerns that 11β-HSD1 inhibition 
may precipitate an adverse proinflammatory phenotype, we 
examined a wider array of inflammatory markers than pre-
vious clinical trials with 11β-HSD1 inhibitors. No changes 
related to AZD4017 treatment over 12 weeks were de-
tected for the inflammatory cytokine levels systemically or 
in the central nervous system. Hence, in a cohort without 
significant chronic inflammatory activity at baseline, our 
study offers further evidence that therapeutic 11β-HSD1 
inhibition does not precipitate inflammation.
Conclusions
In summary, this study provides a metabolic profile for 
the 11β-HSD1 inhibitor AZD4017 in an overweight IIH 
cohort in an extended phase II clinical trial. In particular, 
we demonstrate that it reduces harmful lipid profiles while 
increasing androgen levels and lean muscle mass, without 
having adverse systemic inflammatory or hepatic actions 
although a clinically minimal decline in renal function was 
observed. These beneficial metabolic changes and increases 
in lean muscle mass, not only represent a reduction in risk 
factors associated with IIH, but also indicate new poten-
tial applications for this class of 11β-HSD1 inhibitor in the 
management of sarcopenia and age related muscle wasting.
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